[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.66.254. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
April 11, 2007

Cellular Therapy for Type 1 DiabetesHas the Time Come?

Author Affiliations
 

Author Affiliation: Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Fla.

JAMA. 2007;297(14):1599-1600. doi:10.1001/jama.297.14.1599

Type 1 diabetes mellitus (DM) arises from selective immunologically mediated destruction of the insulin-producing beta cells in the pancreatic islets of Langerhans with consequent insulin deficiency.1,2 This occurs in genetically susceptible individuals and is a cellular-mediated process, presumably a specific reaction to 1 or more beta cell proteins (autoantigens), although probably initiated by some environmental factors. There is consequent progressive impairment of beta cell function and decline in beta cell mass.

First Page Preview View Large
First page PDF preview
First page PDF preview
×